ArticleJournal of Alzheimer's disease : JAD2025
Seizing the link: Exploring the potential association between anti-seizure medications and Alzheimer's disease.
Article in Journal of Alzheimer's disease : JAD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sweetening the Odds: Can Newer Glucose-Lowering Drugs Bend the Arc of Epileptogenesis?Epilepsy currents · 2026Article
- Prodromal changes in cortical neuron physiology before amyloid pathology in a mild model of Alzheimer's disease.Scientific reports · 2026Article
- Epilepsy in the Aging Brain: Time to Rethink the Narrative.Epilepsy currents · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Ongoing seizures in Alzheimer's disease (AD) are associated with worse cognitive and mortality outcomes. However, the relationship between anti-seizure medications (ASMs) and AD remains uncertain. This scoping review of 27 studies (1,241,796 participants) found ASM use to be associated with slightly increased AD risk, though findings were largely inconclusive. Associations between ASMs and AD-related symptoms, including mood, cognition, quality of life, function, and neuropsychiatric symptoms, were similarly mixed. The review establishes the scope of the problem, highlights the gaps, and maps available evidence. However, the included studies have methodological limitations, including inadequate control for the presence and severity of seizures, unclear ASM indications, lack of biomarker-based AD diagnosis, and limited ethnic and racial diversity, which limit conclusions and generalizability. Addressing these gaps in future studies will provide a more nuanced understanding of the relationship between seizures, ASMs, and AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.